ArticleJournal for immunotherapy of cancer2015

Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.

Asim Amin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.